Evaluation of the thrombin generation potential of a recombinant factor IX Fc fusion protein (rFIXFc) in a phase 3 multi-national clinical trial

被引：0
|
作者：
Yang Buyue [1 ]
Jiang, Haiyan [1 ]
Luk, Alvin [1 ]
Pierce, Glenn F. [1 ]
Sommer, Jurg M. [1 ]
机构：
[1] Biogen Idec Inc, Cambridge Ctr 14, Cambridge, MA 02142 USA
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [31] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [32] Individualised Prophylaxis with Recombinant Factor IX FC Fusion Protein (RFIXFC) in Adults/Adolescents With Haemophilia B: Updated Interim Results of the B-YOND Extension Study
    Mahlangu, J. N.
    Shapiro, A. D.
    Pasi, K. J.
    Ragni, M. V.
    Ozelo, M. C.
    Oldenburg, J.
    Matsushita, T.
    Baker, R. I.
    Yuan, H.
    Ferrante, F.
    Ramirez-Santiago, A.
    Lethagen, S.
    Barnowski, C.
    HAEMOPHILIA, 2017, 23 : 85 - 86
  • [33] Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study
    Matsushita, Tadashi
    Mahlangu, Johnny
    Shapiro, Amy D.
    Pasi, K. John
    Ragni, Margaret V.
    Ozelo, Margareth C.
    Oldenburg, Johannes
    Baker, Ross I.
    Yuan, Huixing
    Ramirez-Santiago, Alejandra
    Ferrante, Francesca
    Lethagen, Stefan
    BLOOD, 2016, 128 (22)
  • [34] Subject-Reported Changes in Physical Activity During The B-LONG Study of Recombinant Factor IX FC Fusion Protein (RFIXFC) For Severe Haemophilia B
    Windyga, J.
    Ragni, M.
    Pasi, J.
    Shapiro, A. D.
    Ozelo, M.
    Innes, A.
    Mei, B.
    HAEMOPHILIA, 2015, 21 : 29 - 29
  • [35] Safety, efficacy, and improved pharmacokinetics (PK) demonstrated in a phase 3 clinical trial of extended half-life recombinant FC fusion factor IX (B-LONG)
    Powell, J.
    Ozelo, M.
    Pasi, J.
    Ragni, M.
    Valentino, L.
    Mahlangu, J.
    Josephson, N.
    Perry, D.
    Baker, R.
    Novitzky, N.
    Krassova, S.
    Allen, G.
    Campion, M.
    Jiang, H.
    Li, S.
    Goyal, J.
    Sommer, J.
    Dumont, J.
    Brennan, A.
    Vigliani, G.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2013, 19 : 76 - 77
  • [36] Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study
    Ducore, Jonathan M.
    Fischer, Kathelijn
    Kulkarni, Roshni
    Nolan, Beatrice
    Bennett, Carolyn M.
    Perry, David J.
    Yuan, Huixing
    Ramirez-Santiago, Alejandra
    Ferrante, Francesca
    Lethagen, Stefan
    BLOOD, 2016, 128 (22)
  • [37] Extended-Interval Prophylaxis with Recombinant Factor IX FC Fusion Protein (rFIXFc) in Adults/Adolescents with Haemophilia B: Interim Results of the B-YOND Extension Study
    Mahlangu, J.
    Shapiro, A. D.
    Pasi, K. J.
    Ragni, M. V.
    Ozelo, M. C.
    Oldenburg, J.
    Matsushita, T.
    Baker, R. I.
    Yuan, H.
    Ramirez-Santiago, A.
    Pierce, G. F.
    Allen, G.
    Mei, B.
    HAEMOPHILIA, 2016, 22 : 46 - 47
  • [38] Individualised Prophylaxis In Children With Haemophilia B Treated Long Term With Recombinant Factor Ix Fc Fusion Protein (RFIXFC): Updated Interim Results Of The B-YOND Extension Study
    Fischer, K.
    Kulkarni, R.
    Nolan, B.
    Bennett, C. M.
    Perry, D. J.
    Barnes, C.
    Yuan, H.
    Ramirez-Santiago, A.
    Ferrante, F.
    Dumont, J.
    Lethagen, S.
    Barnowski, C.
    HAEMOPHILIA, 2017, 23 : 94 - 94
  • [39] Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial
    Ettingshausen, Carmen Escuriola
    Hegemann, Inga
    Simpson, Mindy L.
    Cuker, Adam
    Kulkarni, Roshni
    Pruthi, Rajiv K.
    Garly, May-Lill
    Meldgaard, Rikke M.
    Persson, Paula
    Klamroth, Robert
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (02) : 268 - 276
  • [40] Long-term safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) in adults/adolescents with hemophilia B: Longitudinal analysis of B-LONG and B-YOND
    Mahlangu, Johnny
    Ragni, Margaret V.
    Shapiro, Amy D.
    Pasi, K. John
    Ozelo, Margareth C.
    Oldenburg, Johannes
    Matsushita, Tadashi
    Baker, Ross I.
    Feng, Ingyuan
    Ferrante, Francesca
    Ramirez-Santiago, Alejandra
    Mei, Baisong
    Barnowski, Chris
    HAEMOPHILIA, 2016, 22 : 47 - 47
12345